HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Abstract Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. Thes...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/5bfaa35b932a447fac6aa414a235208c |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|